Experimental autoimmune encephalomyelitis (EAE) is an inflammatory demyelinating model commonly used to address debilitating human diseases such as Multiple Sclerosis (MS). It is an important investigative tool for the efficacy testing of new therapeutic compounds.
MOG EAE is induced by immunisation with autoantigens from CNS myelin (MOG 35-55). CNS pathology is driven by the actions of CD4+ T cells activated by the autoantigen. Treatment with test compounds can be carried out prophylactically from the day of immunisation, or therapeutically following disease onset. The standard MOG EAE model provides efficacy data but supportive ex vivo assays are limited. For efficacy and mechanistic data, see Aquila’s MBP-Tracker EAE model.
Other EAE models such as adoptive transfer of pathogenic Th1/Th17 cells to test therapeutic efficacy of compounds are available on request. Please contact us to discuss.